• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Galapagos NV ADR (NQ: GLPG )

    27.48 +0.09 (+0.33%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 26, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 52,003
    Open 27.32
    Bid (Size) 27.41 (2)
    Ask (Size) 27.48 (33)
    Prev. Close 27.39
    Today's Range 27.25 - 27.49
    52wk Range 24.78 - 44.25
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    GLPG Stock Earnings: Galapagos Beats EPS, Misses Revenue for Q1 2024
    GLPG stock results show that Galapagos beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
    Via InvestorPlace
    Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications
    Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next-generation MAGE-A4 TCR T-cell... 
    Via Newsfile

    Performance

    YTD
    -33.53%
    -33.53%
    1 Month
    +7.22%
    +7.22%
    3 Month
    -4.02%
    -4.02%
    6 Month
    -26.74%
    -26.74%
    1 Year
    -33.02%
    -33.02%

    More News

    Read More
    Galapagos Downgraded, Pharma Firm Faces Uphill Battle With Slow Pipeline Progress: Analyst
    Via Benzinga
    Frontier Medicines Announces Oversubscribed $80 Million Series C Financing to Support Progress of Clinical-Stage Pipeline
    From Frontier Medicines
    Via GlobeNewswire
    8 Analysts Have This to Say About Galapagos
    Via Benzinga
    Where Galapagos Stands With Analysts
    Via Benzinga
    JP Morgan Maintains Neutral Rating for Galapagos: Here's What You Need To Know
    Via Benzinga
    Earnings Outlook For Galapagos
    Via Benzinga
    European Drugmaker Galapagos Collaborates With Biotech BridGene Biosciences To Develop Cancer Treatments
    Via Benzinga
    GLPG Stock Earnings: Galapagos Beats EPS, Beats Revenue for Q3 2023
    Via InvestorPlace
    Benzinga's Top Ratings Upgrades, Downgrades For May 8, 2023
    Via Benzinga
    BigCommerce, ContextLogic And Other Big Stocks Moving Lower In Friday's Pre-Market Session
    Via Benzinga
    Earnings Preview For Galapagos
    Via Benzinga
    Where Galapagos Stands With Analysts
    Via Benzinga
    Galapagos' Blood Cancer Candidate Shows 100% Objective Response Rate In Relapsed/Refractory Patients
    Via Benzinga
    Why Galapagos Stock Is Falling Today
    Via Benzinga
    Benzinga's Top Ratings Upgrades, Downgrades For January 23, 2023
    Via Benzinga
    Where Galapagos Stands With Analysts
    Via Benzinga
    Twitter Rolls Out 'Blue For Business,' Visa Pitches Auto-Payments On Ethereum Blockchain, Justin Bieber Slams H&M: Today's Top Stories
    Via Benzinga
    On A Mission As Top European Player, Galapagos Looks For Acquisition Targets
    Via Benzinga
    Benzinga's Top Ratings Upgrades, Downgrades For November 7, 2022
    Via Benzinga
    After FDA, European Agency Limits Use Of Certain JAK Inhibitors Amid Safety Concerns
    Via Benzinga
    Expert Ratings for Galapagos
    Via Benzinga
    3 Biotech Stocks to Sell in October
    Via InvestorPlace
    Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.